Company intelligence / Profile preview

SeptRx

Fremont, California, United Statesseptrx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The SeptRx® Intrapocket PFO Occluder completed a successful first-in-human clinical trial with a reported 100% closure rate and safety out to three years. A larger European InterSEPT CE Mark trial was underway as of early/mid–2010s, with initial enrollment complete and expansion planned. No regulatory approvals or commercial sales have been reported. No recent updates on further development or commercialization.

Therapeutic areas: OtherPulmonologyCardiovascularNeurology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

SeptRx Intrapocket PFO Occluder

Phase 2

Indications: Patent foramen ovale

Beyond the preview

Go deeper on SeptRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeptRx.

Explore the full profile